Table 2.

Median (IQR) costs in USD, by type of provider in first visit, incurred by patients with drug-susceptible pulmonary TB on treatment during January–June 2019, in Bhavnagar (n = 458)

Categories of costs	Total (n = 458) Median (IQR)	Private provider (n = 60) Median (IQR)	Government provider (n = 398) Median (IQR)	P-value
Direct medical	0 (0–0)	30 (10–76)	0 (0–0)	<  0.001
Day charges	0 (0–0)	3 (0–7)	0 (0–0)	<  0.001
Consultation	0 (0–0)	0 (0–0)	0 (0–0)	<  0.001
Radiography	0 (0–0)	4 (0–7)	0 (0–0)	<  0.001
Laboratory	0 (0–0)	4 (0–7)	0 (0–0)	<  0.001
Procedure	0 (0–0)	0 (0–0)	0 (0–0)	0.274
Drug	0 (0–0)	14 (5–55)	0 (0–0)	<  0.001
Prescribed nutrition	0 (0–0)	0 (0–0)	0 (0–0)	0.003
Direct non-medical	3 (2–4)	4 (2–5)	3 (2–4)	<  0.001
Travel to attend health facility	3 (2–4)	4 (2–5)	3 (2–3)	0.002
Food purchased to attend health facility	0 (0–0)	0 (0–0)	0 (0–0)	0.854
Accommodation to attend health facility	0 (0–0)	0 (0–0)	0 (0–0)	0.274
DOT costs (travel)	0 (0–0)	0 (0–0)	0 (0–0)	0.935
Indirect	6 (3–13)	20 (3–76)	4 (3–10)	<  0.001
Loss of wages to attend health facility	3 (0–6)	8 (0–21)	3 (0–6)	0.029
Wage loss of accompanying member	0 (0–3)	0 (0–19)	0 (0–3)	0.84
Household income loss due to TB	0 (0–0)	0 (0–27)	0 (0–0)	0.003
Total costs	8 (5–28)	61 (35–156)	7 (5–14)	<  0.001

IQR Inter-quartile Range; DOT Directly Observed Treatment; USD 1 = INR 70